文献速递神经肿瘤

新型CDK4/6抑制剂联合放疗在弥漫性中线胶质瘤中显示强效抗肿瘤作用

A novel CDK4/6 inhibitor combined with irradiation demonstrates potent anti-tumor efficacy in diffuse midline glioma.
PubMed 文献 · J Neurooncol · 2023-05-03

本研究设计合成新型CDK4/6抑制剂YF-PRJ8-1011,在患者来源DMG细胞及PDX模型中评估其体外、体内抗肿瘤效果及血脑屏障穿透性,并与哌柏西利比较;结果显示YF-PRJ8-1011可抑制DMG细胞生长、穿透血脑屏障、延长小鼠总生存,联合放疗较单用放疗更显著抑制移植瘤生长。

要点

  • YF-PRJ8-1011在体外和体内均可抑制DMG细胞生长。
  • YF-PRJ8-1011可良好穿透血脑屏障。
  • YF-PRJ8-1011联合放疗较单用放疗更显著抑制DMG移植瘤生长。

核心结论

  • YF-PRJ8-1011是一种新型、安全、选择性的CDK4/6抑制剂,可用于DMG治疗。

研究设计与样本

  • 本研究设计并合成新型CDK4/6抑制剂YF-PRJ8-1011,采用患者来源DMG细胞进行体外抗肿瘤效力评估,采用液相色谱串联质谱法测定其通过血脑屏障的活性,并建立DMG患者来源异种移植模型检测其抗肿瘤效力。

主要发现

  • YF-PRJ8-1011在体外和体内均可抑制DMG细胞生长。
  • YF-PRJ8-1011可良好穿透血脑屏障。
  • 与溶媒或哌柏西利相比,YF-PRJ8-1011显著抑制DMG肿瘤生长并延长小鼠总生存。
  • 与哌柏西利相比,YF-PRJ8-1011在体外和体内对DMG均表现出强效抗肿瘤效力。
  • 与单用放疗相比,YF-PRJ8-1011联合放疗对DMG异种移植瘤生长的抑制作用更显著。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Diffuse midline glioma, H3 K27-altered (DMG) is a lethal pediatric brainstem tumor. Despite numerous efforts to improve survival benefits, its prognosis remains poor. This study aimed to design and synthesize a novel CDK4/6 inhibitor YF-PRJ8-1011, which exhibited more potent antitumor activity against a panel of patient-derived DMG tumor cells in vitro and in vivo compared with palbociclib. METHODS: Patient-derived DMG cells were used to assess the antitumor efficacy of YF-PRJ8-1011 in vitro. The liquid chromatography tandem-mass spectrometry method was used to measure the activity of YF-PRJ8-1011 passing through the blood-brain barrier. DMG patient-derived xenograft models were established to detect the antitumor efficacy of YF-PRJ8-1011. RESULTS: The results showed that YF-PRJ8-1011 could inhibit the growth of DMG cells both in vitro and in vivo. YF-PRJ8-1011 could well penetrate the blood-brain barrier. It also significantly inhibited the growth of DMG tumors and prolonged the overall survival of mice compared with vehicle or palbociclib. Most notably, it exerted potent antitumor efficacy in DMG in vitro and in vivo compared with palbociclib. In addition, we also found that YF-PRJ8-1011 combined with radiotherapy also showed more significant inhibition of DMG xenograft tumor growth than radiotherapy alone. CONCLUSION: Collectively, YF-PRJ8-1011 is a novel, safe, and selective CDK4/6 inhibitor for DMG treatment.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Zuo P, Li Y, Wang T, et al. A novel CDK4/6 inhibitor combined with irradiation demonstrates potent anti-tumor efficacy in diffuse midline glioma. J Neurooncol. 2023. PMID: 37133743. doi:10.1007/s11060-023-04323-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。